imbricatolic acid: isolated from Araucaria araucana resin; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| Flora | Rank | Flora Definition | Family | Family Definition |
|---|---|---|---|---|
| Araucaria | genus | A genus of evergreen conifer of the family Araucariaceae, order Pinales, that includes the monkey puzzle (Araucaria araucana).[MeSH] | Araucariaceae | A family of dioecious or monoecious evergreen trees belonging to the order Pinales, subclass Pinidaes, with spirally arranged, narrow or broad leaves often with parallel veins.[MeSH] |
| Araucaria araucana | species | An evergreen tree commonly known as the monkey-puzzle tree. It grows to 1-1.5 m in diameter and 30-40 m in height, and is native to central and southern Chile, and western Argentina. Araucaria araucana is the hardiest among the conifers, and due to its longevity, is often described as a living fossil.[MeSH] | Araucariaceae | A family of dioecious or monoecious evergreen trees belonging to the order Pinales, subclass Pinidaes, with spirally arranged, narrow or broad leaves often with parallel veins.[MeSH] |
| ID Source | ID |
|---|---|
| PubMed CID | 70688370 |
| CHEMBL ID | 2048004 |
| MeSH ID | M0516171 |
| Synonym |
|---|
| imbricatolic acid |
| CHEMBL2048004 |
| bdbm50155758 |
| AKOS032948632 |
| (1s,4ar,5s,8ar)-5-[(3s)-5-hydroxy-3-methylpentyl]-1,4a-dimethyl-6-methylidene-3,4,5,7,8,8a-hexahydro-2h-naphthalene-1-carboxylic acid |
| Excerpt | Relevance | Reference |
|---|---|---|
| " Dose-response experiments on the glycyl derivatives showed that at a single oral dose of 100 mg/kg, the compounds presented an effect comparable to the reference drug lansoprazole at 20 mg/kg and at 50 mg/kg reduced gastric lesions by about 50%." | ( Gastroprotective effect and cytotoxicity of labdeneamides with amino acids. RodrÃguez, JA; Schmeda-Hirschmann, G; Theoduloz, C; Valderrama, JA, 2011) | 0.37 |
| Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| Tyrosine-protein phosphatase non-receptor type 1 | Homo sapiens (human) | IC50 (µMol) | 8.8000 | 0.0005 | 3.4984 | 9.7600 | AID1288133 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID1288137 | Inhibition of human recombinant PTP-1B using IR5 insulin receptor residues as substrate at 30 uM after 30 mins by malachite green assay | 2016 | Bioorganic & medicinal chemistry letters, Apr-15, Volume: 26, Issue:8 | Novel Imbricatolic acid derivatives as protein tyrosine phosphatase-1B inhibitors: Design, synthesis, biological evaluation and molecular docking. |
| AID1288134 | Inhibition of human recombinant PTP-1B using IR5 insulin receptor residues as substrate at 1 uM after 30 mins by malachite green assay | 2016 | Bioorganic & medicinal chemistry letters, Apr-15, Volume: 26, Issue:8 | Novel Imbricatolic acid derivatives as protein tyrosine phosphatase-1B inhibitors: Design, synthesis, biological evaluation and molecular docking. |
| AID1288135 | Inhibition of human recombinant PTP-1B using IR5 insulin receptor residues as substrate at 5 uM after 30 mins by malachite green assay | 2016 | Bioorganic & medicinal chemistry letters, Apr-15, Volume: 26, Issue:8 | Novel Imbricatolic acid derivatives as protein tyrosine phosphatase-1B inhibitors: Design, synthesis, biological evaluation and molecular docking. |
| AID1288136 | Inhibition of human recombinant PTP-1B using IR5 insulin receptor residues as substrate at 10 uM after 30 mins by malachite green assay | 2016 | Bioorganic & medicinal chemistry letters, Apr-15, Volume: 26, Issue:8 | Novel Imbricatolic acid derivatives as protein tyrosine phosphatase-1B inhibitors: Design, synthesis, biological evaluation and molecular docking. |
| AID1288133 | Inhibition of human recombinant PTP-1B using IR5 insulin receptor residues as substrate after 30 mins by malachite green assay | 2016 | Bioorganic & medicinal chemistry letters, Apr-15, Volume: 26, Issue:8 | Novel Imbricatolic acid derivatives as protein tyrosine phosphatase-1B inhibitors: Design, synthesis, biological evaluation and molecular docking. |
| AID1288138 | Inhibition of human recombinant PTP-1B using IR5 insulin receptor residues as substrate at 100 uM after 30 mins by malachite green assay | 2016 | Bioorganic & medicinal chemistry letters, Apr-15, Volume: 26, Issue:8 | Novel Imbricatolic acid derivatives as protein tyrosine phosphatase-1B inhibitors: Design, synthesis, biological evaluation and molecular docking. |
| AID670832 | Antidiabetic activity in rat L6 cells assessed as stimulation of glucose uptake at 10 uM | 2012 | Bioorganic & medicinal chemistry letters, Jul-15, Volume: 22, Issue:14 | Synthesis of novel imbricatolic acid analogues via insertion of N-substituted piperazine at C-15/C-19 positions, displaying glucose uptake stimulation in L6 skeletal muscle cells. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (28.57) | 29.6817 |
| 2010's | 5 (71.43) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.75) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 7 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||